Abstract:Introduction HIV-1, the primary causative agent of AIDS, remains a formidable and lethal virus globally, claiming the lives of millions over the past four decades since its discovery. Recent research has underscored the potential of HIV-1 protease as a therapeutic target, offering a promising strategy for inhibiting viral replication within the body.Method In light of this, we have curated an extensive database comprising 193 derivatives of Darunavir (DRV), an HIV-1 protease inhibitor. Simultaneously, we have developed a comprehensive set of 3D-QSAR models to elucidate the structure-activity relationships of these 193 derivative inhibitors. Employing various computational simulation techniques, including Comparative Molecular Field Analysis (CoMFA), Comparative Similarity Indices Analysis (CoMSIA), and molecular docking, we have unveiled the fundamental three-dimensional structural features influencing their biological activity.Result Results indicate that the optimal CoMSIA model (Q2 = 0.500, R2ncv = 0.882, R2pred = 0.797) surpasses other models, demonstrating superior predictive capability. Furthermore, docking results suggest that DRV derivatives maintain stable conformations within the binding cavity due to synergistic interactions, such as hydrogen bonding and non-bonded interactions. Drawing insights from the best computational models, we have designed five DRV derivatives with significant HIV-1 protease inhibitory activity through local modification, with theoretical calculations indicating favorable pharmacokinetic properties and synthetic feasibility for the newly proposed molecules.Conclusion It is hoped that the findings and conclusions obtained herein may furnish theoretical underpinning and directional guidance for the design, optimization, and experimental synthesis of DRV derivative compounds for pharmaceutical purposes.

Novel HIV-1 Protease Inhibitors with Morpholine As the P2 Ligand to Enhance Activity Against DRV-Resistant Variants

Design, Synthesis and Biological Evaluation of HIV-1 Protease Inhibitors with Morpholine Derivatives As P2 Ligands in Combination with Cyclopropyl As P1' Ligand.

Design, synthesis and biological evaluation of protease inhibitors containing morpholine cores with remarkable potency against both HIV-1 subtypes B and C

Design and Evaluation of Novel HIV-1 Protease Inhibitors Containing Phenols or Polyphenols as P2 Ligands with High Activity against DRV-Resistant HIV-1 Variants

A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants

Design and Evaluation of Novel Piperidine HIV-1 Protease Inhibitors with Potency Against DRV-resistant Variants

Preliminary SAR and Biological Evaluation of Potent HIV-1 Protease Inhibitors with Pyrimidine Bases As Novel P2 Ligands to Enhance Activity Against DRV-resistant HIV-1 Variants

Design, Synthesis, and Biological Evaluation of Novel HIV-1 Protease Inhibitors Containing Pyrrolidine-Derived P2 Ligands to Combat Drug-Resistant Variant

Design and Biological Evaluation of Novel HIV-1 Protease Inhibitors with Isopropanol As P1′ Ligand to Enhance Binding with S1′ Subsite

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility

Piperidine Scaffold As the Novel P2-ligands in Cyclopropyl-Containing HIV-1 Protease Inhibitors: Structure-based Design, Synthesis, Biological Evaluation and Docking Study

Synthesis and evaluation of potent human immunodeficiency virus 1 protease inhibitors with epimeric isopropanol as novel P1 ligands

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

Design and Biological Evaluation of Cinnamic and Phenylpropionic Amide Derivatives As Novel Dual Inhibitors of HIV-1 Protease and Reverse Transcriptase

Design, Synthesis, and Biological Evaluation of Novel 5-Alkyl-6-adamantylmethylpyrimidin-4(3h)-ones As Hiv-1 Non-Nucleoside Reverse-Transcriptase Inhibitors

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency Against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.

Design, Synthesis and Anti-Hiv Evaluation of Novel Diarylpyridine Derivatives Targeting the Entrance Channel of NNRTI Binding Pocket.

Unveiling Novel HIV-1 Protease Inhibitors Through an Integrated Analysis of 3D-QSAR, Molecular Docking, and Binding Free Energy

Discovery of 2-Pyridone Derivatives As Potent HIV-1 NNRTIs Using Molecular Hybridization Based on Crystallographic Overlays.